Vemurafenib in the Treatment of Erdheim Chester Disease: A Systematic Review.
| Autor: | Aziz SN; Internal Medicine, Shaheed Suhrawardy Medical College, Dhaka, BGD., Proano L; Internal Medicine, Pontificia Universidad Católica del Ecuador, Quito, ECU., Cruz C; General Medicine, Universidad San Francisco de Quito, Quito, ECU., Tenemaza MG; School of Medicine, Universidad San Francisco de Quito, Quito, ECU., Monteros G; General Medicine, Pontificia Universidad Católica del Ecuador, Quito, ECU., Hassen G; Internal Medicine, University of Maryland Capital Region Medical Center, Largo, USA.; Medicine, Addis Ababa University, Addis Ababa, ETH.; Progressive Care, Mercy Medical Center, Baltimore, USA.; Medicine and Surgery, Parma University, Parma, ITA., Baskar A; Medicine and Surgery, K.A.P Viswanatham Government Medical College, Tiruchirappalli, IND., Argudo JM; Child Neurology, Universidad de Cuenca, Cuenca, ECU., Duenas JB; Internal Medicine, Universidad Central del Ecuador, Quito, ECU., Fabara SP; Internal Medicine, North Florida Regional Medical Center, Gainesville, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Jun 14; Vol. 14 (6), pp. e25935. Date of Electronic Publication: 2022 Jun 14 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.25935 |
| Abstrakt: | Erdheim Chester disease (ECD) is a type of histiocytosis characterized by a variable clinical presentation. The treatment of ECD is complex and mainly unknown. We aim to conduct a literature review of the treatment of ECD and consolidate the knowledge about the most recent and updated treatment for ECD. To conduct the systematic review, we used the preferred reporting items for systematic reviews and meta-analysis (PRISMA) protocol. To analyze the bias, we used the Cochrane collaboration risk-of-bias tool to assess the bias. We included observational studies and clinical trials on humans, which were written in English. Papers not fulfilling the objective of our study were excluded. Overall, the drug showed efficacy in the clinical trials, showing prolonged improvement and high rates of response rate. Overall, the drug was not well tolerated, and patients had a long list of side effects. Nevertheless, the drug seems to be a good option for second-line treatment for patients with ECD and BRAFV600 mutation. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Aziz et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|